FIELD: medicine.
SUBSTANCE: invention is designed to determine the risk of breast cancer recurrence. The expression level of ELOVL5, IGFBP6, TXNDC9 marker genes is measured in the patient tumour tissue sample. The risk of recurrence is assessed by comparing the expression levels of marker genes to predetermined threshold values.
EFFECT: invention provides a simple, sensitive, reliable way of disease-free survival prediction.
14 cl, 6 dwg, 8 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SET OF REAGENTS FOR DETERMINING THE RISK OF RECURRENCE OF BREAST CANCER | 2017 |
|
RU2671557C1 |
| METHODS AND KITS FOR MOLECULAR SUBTYPING OF TUMORS | 2014 |
|
RU2690241C2 |
| SET OF SYNTHETIC OLIGONUCLEOTIDES FOR DETERMINATION OF LEVELS OF GENE PDLIM4 EXPRESSION | 2015 |
|
RU2612139C1 |
| METHOD FOR PREDICTING RISK OF BREAST CANCER PROGRESSION WITH UNDERLYING TAMOXIFEN TAKING INTO ACCOUNT EXPRESSION CHARACTERISTICS OF TUMOUR | 2023 |
|
RU2823488C1 |
| DIAGNOSTIC TECHNIQUE FOR BLADDER CANCER (VERSIONS) AND KIT FOR IMPLEMENTATION THEREOF | 2011 |
|
RU2469323C2 |
| METHOD OF SCREENING AND MONITORING CANCEROUS DISEASES AND KIT THEREFOR (VERSIONS) | 2012 |
|
RU2537263C2 |
| SET OF OLIGODEOXYRIBONUCLEOTIDE PRIMERS AND FLUORESCENTLY LABELED DNA PROBES FOR DETERMINING THE EXPRESSION OF THE SOCS2, CD34, FAM30A, GPR56, DNMT3B, SPINK2 GENES, FOLLOWED BY DETERMINING THE LEVEL OF RELATIVE EXPRESSION RELATIVE TO THE ABL1 REFERENCE GENE, AMPLIFIED IN REAL-TIME PCR, USED TO PREDICT THE RISK OF EARLY RELAPSE IN CHILDREN WITH ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | 2022 |
|
RU2783950C1 |
| METHOD FOR DIAGNOSING ACUTE LEUKEMIA AND KITS FOR ITS IMPLEMENTATION | 2021 |
|
RU2806591C2 |
| METHOD FOR DIAGNOSING BREAST CANCER BY LEVEL OF EXPRESSION OF IL-10 AND/OR IL-17 MRNA IN BLOOD PLASMA | 2020 |
|
RU2752971C1 |
| METHOD OF DIAGNOSING CLEAR CELL RENAL CELL CARCINOMA AND SET FOR ITS REALISATION | 2012 |
|
RU2545998C2 |
